Cefepime-related encephalopathy in peritoneal dialysis patients

Journal of the Chinese Medical Association

Volumn 74, Issue 2, 2011, Pages 87-90

  Lin, Chun Jen ^a,b   Chen, Shih Pin ^a,b   Wang, Shuu Jiun ^a,b   Fuh, Jong Ling ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Cefepime; Electroencephalogram; Encephalopathy; Peritoneal dialysis

Indexed keywords

C REACTIVE PROTEIN; CEFEPIME; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM;

AGED; AGITATION; ARTICLE; ATAXIA; BRAIN DISEASE; CASE REPORT; CHRONIC KIDNEY FAILURE; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; DELIRIUM; DISORIENTATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSMETRIA; DYSTONIA; ELECTROENCEPHALOGRAM; ENDOMETRITIS; FEMALE; FLAPPING TREMOR; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; LEUKOARAIOSIS; LEUKOCYTOSIS; MENTAL HEALTH; MINI MENTAL STATE EXAMINATION; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITONEAL DIALYSIS; PNEUMONIA; SIDE EFFECT; SPEECH DISORDER;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BRAIN DISEASES; CEPHALOSPORINS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS;

EID: 79951945404     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/j.jcma.2011.01.017     Document Type: Article

References (20)

1. Barbhaiya R.H., Forgue S.T., Gleason C.R., Knupp C.A., Pittman K.A., Weidler D.J., et al. Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses. Antimicrob Agents Chemother 1990, 34:1118-1122.
2. Barradell L.B., Bryson H.M. Cefepime: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic use. Drugs 1994, 3:471-505.
3. Jallon P., Fankhauser L., Pasquier R.D., Coeytaux A., Picard F., Assal F. Severe but reversible encephalopathy associated with cefepime. Neurophysiol Clin 2000, 30:383-386.
4. Martínez-Rodríguez J.E., Barriga F.J., Santamaria J., Iranzo A., Pareja J.A., Revilla M., et al. Nonconvulsive status epilepticus associated with cephalosporin in patients with renal failure. Am J Med 2001, 111:115-119.
5. Lam S., Pharm D., Irving H. Cefepime neurotoxicity: case report, pharmacokinetic considerations, and literature review. Pharmacotherapy 2006, 26:1169-1174.
6. Chow K.M., Wang Y.M., Hui C.F., Wong Y.H., Szeto C.C., Li K.T. Nonconvulsive status epilepticus in peritoneal dialysis patients. Am J Kidney Dis 2001, 38:400-405.
7. Chow K.M., Szeto C.C., Hui C.F., Wong Y.H., Li K.T. Retrospective review of neurotoxicity induced by cefepime and ceftazidime. Pharmacotherapy 2003, 23:369-373.
8. Grill M.F., Maganti R. Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the roles of electroencephalographic monitoring. Ann Pharmacother 2008, 42:1843-1850.
9. Alpay H., Altun Ö, Biyikli N. Cefepime-induced non-convulsive status epilepticus in a peritoneal dialysis patient. Pediatr Nephrol 2004, 19:445-447.
10. Maganti R., Jolin D., Rishi D., Biswas A. Nonconvulsive status epilepticus due to cefepime in a patient with normal renal function. Epilepsy Behav 2006, 8:312-314.
11. Capparelli F.J., Diaz M.F., Hlavnika A., Wainsztein N.A., Leiguarda R., Del Castillo M.E. Cefepime- and cefixime-induced encephalopathy in a patient with normal renal function. Neurology 2005, 65:1840.
12. Garcés E.O., Azambuja M.F., Silva D., Bragatti J.A., Jacoby T., Thomé F.S. Renal failure is a risk factor for cefepime-induced encephalopathy. J Nephrol 2008, 21:525-534.
13. Hammami N., Drissi C., Sebai R., Araar M., Maatallah Y., Belghith L., et al. Reversible metronidazole-induced encephalopathy. J Neuroradiol 2007, 34:133-136.
14. Sugimoto M., Uchida I., Mashimo T., Yamazaki S., Hatano K., Ikeda F., et al. Evidence for the involvement of GABA(A) receptor blockade in convulsions induced by cephalosporins. Neuropharmacology 2003, 45:304-314.
15. Sugimoto M., Fukami S., Kayakiri H., Yamazaki S., Matsuoka N., Uchida I., et al. The beta-lactam antibiotics, penicillin-G and cefoselis have different mechanisms and sites of action at GABA(A) receptors. Br J Pharmoacol 2002, 135:427-432.
16. Wallace K.L. Antibiotic-induced convulsions. Crit Care Clin 1997, 13:741-762.
17. Bragatti J.A. Cefepime-induced neurotoxicities. Cent Nerv Syst Agents Med Chem 2008, 8:229-233.
18. Alkharfy K.M., Kellum J.A., Frye R.F., Matzke J.R. Effect of ceftazidime on systemic cytokine concentrations in rats. Antimicrob Agents Chemother 2000, 44:3217-3219.
19. Barbhaiya R.H., Knupp C.A., Pfeffer M., Zaccardelli D., Dukes G.M., Mattern W., et al. Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1992, 36:1387-1391.
20. Barbhaiya R.H., Forgue S.T., Gleason C.R., Knupp C.A., Pittman K.A., Weidler D.J., et al. Pharmacokinetics of cefepime after single and multiple intravenous administration in healthy subjects. Antimicrob Agents Chemother 1992, 36:552-557.